Resorption enhancers as additives to improve the oral formulation of low molecular weight heparins
AssigneesBaxter Healthcare S.A., Baxter International Inc.
InventorsPeter Turecek, Susanne Vejda
Life of this patent
Estimating the term…
Abstract
Aspects of the invention include methods for treating or preventing a thromboembolic disease in a subject. In practicing methods according to certain embodiments, an amount of a low molecular weight heparin (LMWH) and a synergistically effective combination of two or more gastrointestinal epithelial barrier permeation enhancers is orally administered to a subject in a manner sufficient to treat the thromboembolic disease in the subject. Compositions and kits for practicing methods of the invention are also described.
Claims22
An oral dosage composition comprising:
- a low-molecular weight heparin;
- a synergistically effective combination of two or more gastrointestinal epithelial barrier permeation enhancers;
- and
- an oral dosage delivery vehicle.
17-28. (canceled)
An oral dosage composition comprising:
- a low-molecular weight heparin;
- a synergistically effective combination of unmodified chitosan and bromelain in an amount sufficient to provide gastrointestinal epithelial barrier permeation enhancement that is greater than is achieved by the additive sum of unmodified chitosan and bromelain individually;
- and
- an oral dosage delivery vehicle.
30-43. (canceled)
A method comprising:
- orally administering to a subject an oral dosage composition comprising:
- a low molecular weight heparin;
- a synergistically effective combination of two or more gastrointestinal epithelial barrier permeation enhancers;
- and
- an oral dosage delivery vehicle.
46-103. (canceled)
Dependencies are inferred from the claim text.